Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Auner HW, Szydlo R, Rone A, Chaidos A, Giles C, Kanfer E et al. Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. Leuk Lymphoma 2013; 54: 2200–2204.

    Article  Google Scholar 

  2. Shah N, Ahmed F, Bashir Q, Qureshi S, Dinh Y, Rondon G et al. Durable remission with salvage second autotransplants in patients with multiple myeloma. Cancer 2012; 118: 3549–3555.

    Article  Google Scholar 

  3. Lemieux E, Hulin C, Caillot D, Tardy S, Dorvaux V, Michel J et al. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 445–449.

    Article  CAS  Google Scholar 

  4. Cook G, Williams C, Brown JM, Cairns DA, Cavenagh J, Snowden JA et al. High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI myeloma × relapse (Intensive trial)): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 874–885.

    Article  CAS  Google Scholar 

  5. Kumar SK, Lacy MQ, Hayman SR, Stewart K, Buadi FK, Allred J et al. Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial. Am J Hematol 2011; 86: 640–645.

    Article  CAS  Google Scholar 

  6. van de Donk NW, Wittebol S, Minnema MC, Lokhorst HM . Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma. Br J Haematol 2010; 148: 335–337.

    Article  CAS  Google Scholar 

  7. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

    Article  CAS  Google Scholar 

  8. Thall PF, Cook JD . Dose-finding based on efficacy-toxicity trade-offs. Biometrics 2004; 60: 684–693.

    Article  Google Scholar 

  9. Fisher R . On the interpretation of χ2 from contingency tables, and the calculation of P. J R Stat Soc 1922; 85: 87–94.

    Article  Google Scholar 

  10. Freeman GH, Halton JH . Note on exact treatment of contingency, goodness of fit and other problems of significance. Biometrika 1951; 38: 141–149.

    Article  CAS  Google Scholar 

  11. Gelman ACJ, Stern HS, Rubin DB . Bayesian Data Analysis 2nd edn. Chapman & Hall/CRC Press: New York, NY, USA, 2004.

    Google Scholar 

  12. Ibrahim JG, Chen M-H, Sinha D . Bayesian Survival Analysis. Springer: New York, NY, 2001.

    Book  Google Scholar 

  13. Doo NW, Thompson PA, Prince HM, Seymour JF, Ritchie D, Stokes K et al. Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma. Leuk Lymphoma 2013; 54: 1465–1472.

    Article  Google Scholar 

  14. Orlowski RZ . Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. Semin Oncol 2013; 40: 634–651.

    Article  CAS  Google Scholar 

  15. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149–157.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N Shah.

Ethics declarations

Competing interests

Drs N Shah, Bashir, JJ Shah, Hosing and Orlowski receive research funding from Celgene. Drs N Shah, JJ Shah and Orlowski have served on Celgene Advisory Boards.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shah, N., Thall, P., Fox, P. et al. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia 29, 1945–1948 (2015). https://doi.org/10.1038/leu.2015.54

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2015.54

This article is cited by

Search

Quick links